布地奈德联合特布他林雾化吸入对小儿支气管哮喘的疗效

Effect of budesonide combined with aerosol inhalation of terbutaline in treating bronchial asthma children

  • 摘要: 目的 观察布地奈德联合特布他林雾化吸入对小儿支气管哮喘的疗效,并探讨对血清环氧化酶-2(COX-2)、趋化素样因子-1(CKLF-1)的影响。 方法 选取小儿支气管哮喘患儿100例为研究对象,采用随机数表法将患者分为2组,每组50例。对照组采用布地奈德治疗,观察组在此基础上联合特布他林雾化吸入治疗。比较2组治疗效果及患儿症状缓解时间、住院时间。观察治疗前后用力肺活量(FVC)、第1秒用力呼气量(FEV1)、第1秒用力呼气量占用力肺活量比值(FEV1/FVC)、COX-2、CKLF-1的变化,同时比较2组不良反应发生情况。 结果 观察组总有效率高于对照组,差异有统计学意义(P<0.05)。观察组胸闷、喘息、咳嗽改善时间及住院时间均短于对照组,差异有统计学意义(P<0.05)。与治疗前比较, 2组FVC、FEV1、FEV1/FVC均升高,且观察组高于对照组,差异有统计学意义(P<0.05)。治疗后, 2组患儿COX-2、CKLF-1表达水平低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。 结论 布地奈德联合特布他林雾化吸入治疗小儿支气管哮喘可有效缓解患儿临床症状,降低血清COX-2、CKLF-1表达水平,促进肺功能恢复,缩短患儿住院时间。

     

    Abstract: Objective To observe the effect of budesonide combined with aerosol inhalation of terbutaline in children with bronchial asthma and the influence on serum cyclooxygenase-2(COX-2)and chemokine like factor-1(CKLF-1). Methods A total of 100 children with bronchial asthma were selected as study objects, and were divided into two groups according to random number table method, with 50 cases in each group. The control group was treated with budesonide, and the observation group was treated with aerosol inhalation of terbutaline based on the control group. Treatment effect, symptom relief time and hospitalization time were compared. The changes of forced vital capacity(FVC), forced expiratory capacity in the first second(FEV1), ratio of forced expiratory capacity in the first second to forced vital capacity(FEV1/FVC), COX-2, CKLF-1 before and after treatment in two groups were recorded, and the occurrence of adverse reactions of two groups was recorded. Results The total effective rate in the observation group was significantly higher than that in the control group(P<0.05). Children in the observation group had shorter improvement time in chest tightness, wheezing, cough and hospitalization time than the control group(P<0.05). Compared with before treatment, the levels of FVC, FEV1, FEV1/FVC in two groups were all increased, and the observation group was higher than the control group, the differences were statistically significant(P<0.05). After treatment, the expression levels of COX-2 and CKLF-1 in the two groups were significantly lower than before treatment, and the observation group was significantly lower than - the control group(P<0.05). The incidence rate of adverse reactions in the observation group was significantly lower than that in the control group(P<0.05). Conclusion Budesonide combined with atomization inhalation of terbutaline can effectively alleviate the clinical symptoms of children with bronchial asthma, reduce the expression levels of serum COX-2 and CKLF-1, promote the recovery of lung function, and shorten the hospitalization time.

     

/

返回文章
返回